share_log

Transcode Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Transcode Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Transcode Therapeutics | DEFR14A:修正後委託徵集材料
美股sec公告 ·  05/21 04:01
牛牛AI助理已提取核心訊息
TransCode Therapeutics, Inc. (TransCode) has announced the filing of a DEFR14A form with the United States Securities and Exchange Commission (SEC), which includes a Proxy Statement and an amendment to the company's Definitive Proxy Statement on Schedule 14A. The Proxy Statement, filed on May 20, 2024, outlines proposals for the upcoming 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. The key proposals include the election of four directors, approval of an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares, ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approval of a reverse stock split of common stock at a ratio ranging from 1:2 to...Show More
TransCode Therapeutics, Inc. (TransCode) has announced the filing of a DEFR14A form with the United States Securities and Exchange Commission (SEC), which includes a Proxy Statement and an amendment to the company's Definitive Proxy Statement on Schedule 14A. The Proxy Statement, filed on May 20, 2024, outlines proposals for the upcoming 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. The key proposals include the election of four directors, approval of an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares, ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approval of a reverse stock split of common stock at a ratio ranging from 1:2 to 1:40 at the board's discretion. Additionally, the Proxy Statement proposes to adjourn the Annual Meeting to a later date if necessary to permit further solicitation of proxies. The Proxy Statement replaces the Original Proxy Statement filed on April 29, 2024, and includes updated information regarding the annual meeting, which may be held virtually if in-person attendance is not possible or advisable. The company has advised stockholders to vote their shares by proxy prior to the Annual Meeting.
TransCode Therapeutics, Inc.(TransCode)宣佈向美國證券交易委員會(SEC)提交一份 DEFR14A 表格,其中包括一份委託書和對該公司附表14A的最終委託書的修正案。2024年5月20日提交的委託書概述了定於2024年6月13日舉行的2024年年度股東大會的提案。主要提案包括選舉四名董事,批准將公司2021年股票期權和激勵計劃下的可用股票數量增加300萬股的修正案,批准WithumSmith+Brown作爲截至2024年12月31日的財政年度的獨立註冊會計師事務所,以及批准董事會酌情按照 1:2 至 1:40 的比例對普通股進行反向分割。此外,委託書提議,必要時將年會延期,以允許進一步徵集代理人。委託書取代了2024年4月29日提交的原始委託聲明,幷包含有關年會的最新信息,如果不可能或不建議親自出席,年度會議可能會以虛擬方式舉行。該公司已建議股東在年會之前通過代理人對股票進行投票。
TransCode Therapeutics, Inc.(TransCode)宣佈向美國證券交易委員會(SEC)提交一份 DEFR14A 表格,其中包括一份委託書和對該公司附表14A的最終委託書的修正案。2024年5月20日提交的委託書概述了定於2024年6月13日舉行的2024年年度股東大會的提案。主要提案包括選舉四名董事,批准將公司2021年股票期權和激勵計劃下的可用股票數量增加300萬股的修正案,批准WithumSmith+Brown作爲截至2024年12月31日的財政年度的獨立註冊會計師事務所,以及批准董事會酌情按照 1:2 至 1:40 的比例對普通股進行反向分割。此外,委託書提議,必要時將年會延期,以允許進一步徵集代理人。委託書取代了2024年4月29日提交的原始委託聲明,幷包含有關年會的最新信息,如果不可能或不建議親自出席,年度會議可能會以虛擬方式舉行。該公司已建議股東在年會之前通過代理人對股票進行投票。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。